GLPwatch
Multilayer nanoparticles for sustained delivery of exenatide to treat type 2 diabetes mellitus.
Biomaterials · 2013
Last updated 2026-05-28Researchers developed a method to deliver the diabetes drug exenatide using layered nanoparticles, which slowly release the medication over time. In animal tests, these nanoparticles helped control blood sugar, and the drug remained stable after release. The study also examined how different nanoparticle structures affected the drug's release and effectiveness.
AI summary of the abstract below.
| Journal | Biomaterials, 2013 |
|---|---|
| Citations | 30 |
| Relative citation ratio | 1.08 |
| NIH percentile | 53 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
A method for the sustained delivery of exenatide was proposed using nanoparticles (NPs) with a core/shell structure. The interactions between lipid bilayers and Pluronics were utilized to form various NPs using a layer-by-layer approach. Transmittance electron microscopy and dynamic light scattering were used to examine the morphology of the NPs. The in vitro release pattern was observed as a function of changes in the structure of the NPs, and the structural integrity of exenatide released was examined by SDS-PAGE analysis. Pharmacokinetics and antidiabetic effects were also observed with the structural change of NPs using in vivo animal models. In vitro-in vivo correlation was discussed in relation to manipulation of the NP structures.
Verbatim abstract via PubMed 23895999 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.